ICOSLG antibody (AA 201-250)
Quick Overview for ICOSLG antibody (AA 201-250) (ABIN7227726)
Target
See all ICOSLG AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 201-250
-
Purpose
- CD275 Polyclonal Antibody
-
Specificity
- The antibody detects endogenous levels of CD275
-
Purification
- The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen
-
Immunogen
- Synthesized peptide derived from part region of human CD275 protein at AA range: 201-250
-
Isotype
- IgG
-
-
-
-
Application Notes
- Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC-P (1:50-1:200), ELISA (1:10000-1:20000).
-
Comment
-
Primary Antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- PBS, pH 7.4, containing 0.02 % Sodium Azide as preservative and 50 % Glycerol as stabilizer.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
-
-
- ICOSLG (Inducible T-Cell Co-Stimulator Ligand (ICOSLG))
-
Alternative Name
- CD275
-
Background
- Rabbit Anti-CD275 Polyclonal Antibody,ICOS ligand, B7 homolog 2, B7-H2, B7-like protein Gl50, B7-related protein 1, B7RP-1, CD antigen CD275,ICOSLG (Inducible T-Cell Costimulator Ligand) is a Protein Coding gene. Diseases associated with ICOSLG include Inclusion Body Myositis and Immunodeficiency With Hyper-Igm, Type 2. Among its related pathways are Immune response NFAT in immune response and T Cell Co-Signaling Pathway: ligand-Receptor Interactions.,CD275
-
Gene ID
- 23308
-
UniProt
- O75144
-
Pathways
- Production of Molecular Mediator of Immune Response, Activated T Cell Proliferation
Target
-